{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT OR AST > 3XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT OR AST> 5XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT OR AST> 10XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT OR AST > 20XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"TOTAL BILIRUBIN > 2XULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALP > 1.5xULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1 DAY"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 30 DAYS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"title":"ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"},{"groupId":"OG001","value":"345"}],"units":"Participants"}],"description":"The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units.","groups":[{"description":"Participants receive BMS-986213 (IV fixed-dose combination relatlimab/nivolumab at a 1:3 ratio) every 4 weeks (Q4W).\n\nFor adults, dosing is relatlimab 160 mg/nivolumab 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is relatlimab 2 mg/kg/nivolumab 6 mg/kg.","id":"OG000","title":"Arm A: Relatlimab + Nivolumab"},{"description":"Participants receive Nivolumab IV monotherapy every 4 weeks (Q4W).\n\nDosing for adults is 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is 6 mg/kg.","id":"OG001","title":"Arm B: Nivolumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants with at least one on-treatment measurement of the corresponding laboratory parameter","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days after last dose of study therapy (up to approximately 33 months)","title":"The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}